Onofrio Laselva

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator

Onofrio Laselva, Claire Bartlett, T. Gunawardena et al. · European Respiratory Journal · 2020 · 164 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue

Steven V. Molinski, Saumel Ahmadi, Wan Ip et al. · EMBO Molecular Medicine · 2017 · 105 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action

Onofrio Laselva, Paul D. W. Eckford, Claire Bartlett et al. · Journal of Cystic Fibrosis · 2019 · 70 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site

Steven V. Molinski, Vijay Shahani, Adithya S. Subramanian et al. · Proteins Structure Function and Bioinformatics · 2018 · 61 citations

Life Sciences, Genetics, Molecular Biology +16

Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains

Onofrio Laselva, Steven V. Molinski, Valeria Casavola et al. · Molecular Pharmacology · 2018 · 58 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16